Lori and guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
> Listen on iHeart
In the second part of the discussion, our guests address clinical trial design which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.
Using specific examples, our guests highlight the progress the industry has made to design inclusive clinical trials but stress the continuing need for improvement.
In parallel, our guests discuss the continual judicial actives at the federal and state level surrounding women’s health issues. As states begin to challenge other states for access to women’s data, the future participation of women patients in clinical trials is becoming uncertain.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Otis Johnson, PhD, MPA, Principal Consultant and Co-founder, Trial Equity
Pamela Tenaerts, MD, MBA, Chief Science Officer, Medable
Chris Hart, Partner, Co-Chair, Privacy and Data Security Group, Foley Hoag LLP
Patrick Floody, Executive Director, Global Clinical Trial Services, Regeneron
Ken Getz, Executive Director, Tufts Center for the Study of Drug Development; Professor, Tufts University School of Medicine
Disclaimer: The views expressed in this discussion by Patrick Floody are his own and do not represent those of Regeneron.
